| |
|
|
|
Zerosum
has a board of advisors consisiting of several individuals
who are specialists in their respective fields and who bring
important domain knowledge to our business goals.
Marketing
& Business Development
Dr. Michael
Kayat
Founder
and Managing Principal Partner of Metrisys, LLC
Dr. Kayat holds a Ph.D in Physics from the University
of Leicester, UK and an MBA from the Graziado School of Business,
Pepperdine University. Dr. Kayat has nearly 20 years experience
in the IT industry and has gained substantial experience in
sales, marketing and business development with Fortune 1000
and Global 2000 clients in a wide range of industries. He
has held senior roles, as Director and Vice President, in
the consulting services, software and supercomputer industries.
He began his career as a Senior consultant in Aerospace and
Defense at Logica, an international consulting services firm
managing large scale software projects before moving into
sales. While at Logica he successfully launched products and
services into the North American aerospace, defense, manufacturing
and life sciences markets. As a senior sales executive at
supercomputer companies Alliant Computer Systems and Convex
Computer Corporation, he worked with clients in many industries,
involved in advanced applications including bioinformatics
within the Biotech and Pharmaceutical companies. At SGI he
was a sales leader in the emerging web-based database-driven
content applications working with some of the most successful
new economy companies. At two start-up sofware companies,
i-Logix and Exa, he led sales to record levels and helped
position these companies for sustained solid growth. While
at Exa, he and his team launched the first ever technical
computing application service provider (ASP). As senior executive
at consulting services company Integris, part of international
IT company Bull, he launched several new services including
e-commerce and e-marketplace ASPs, managed infrastructure
security services and an extensive portfolio of network services.
He and his team executed best practices to achieve high levels
of service and reliability. Michael Kayat is now the founder
and the Managing Principal Partner of Metrisys, LLC, a consulting
company that provides strategy, sales and marketing services.
Metrisys is focused on advanced technology emerging companies
in the High Tech and Life Sciences industries.
Advisory
Board member since 2002.
Corporate
Counsel
Rodney
A. Beard, Esq.,
attorney
Beard has been a Zerosum advisor since 1987. He practiced
law in State College, Pennsylvania, and his firm is now known
as Rodney A. Beard, P.C. Prior to forming this firm (formerly
known as Beard & Richards), Mr. Beard was a shareholder in
Kalin & Beard, Ltd. Mr. Beard has recently served as CEO of
ZedX, Inc., an information technology company located in Bellefonte,
Pennsylvania.
In his practice, Mr. Beard has emphasized business and commercial
work, with a focus on intellectual property, software and
computer applications, start-up enterprises (including for-profit
and non-profit corporations, limited and general partnerships,
limited liability companies, and sole proprietorships), business
planning and opportunities (including financing and expansion),
contracts, employment issues, and technology-related ventures.
He works with several software and data distribution companies,
and has assisted many clients with procuring and protecting
trademarks, copyrights, and other forms of intellectual property.
He also has been involved in licensing and technology transfer
ventures.
Advisory
Board member since 1987.
Bioinformatics
Dr.
Stephen Holbrook,
Staff scientist at Lawrence Berkeley National Laboratory
Dr. Holbrook is an experienced macromolecular crystallographer
specializing in structural studies of RNA and Protein-nucleic
acid complexes. He is currently leading a project studying
the structural basis of DNA repair in the radiation resistant
microbe Deinococcus radiodurans. He also has been involved
in computational biology projects for many years, from crystallographic
computing, to molecular modeling of nucleic acids and proteins,
to machine learning approaches to biological questions. He
has developed neural networks for the prediction of protein
surface accessibility, disulfide bonding state, and protein
fold classification. He is currently developing methods for
finding novel RNA genes in genomic sequences, assignment of
biological function directly from protein sequence and classification
of bacterial promoter seqeunces.
Advisory
Board member since 2001.
Bioinformatics
Dr.
Izabela Makalowska,
Director, Center for Computational Genomics Life Sciences
Consortium
The Pennsylvania State University
Education
M.Sc., Adam Mickiewicz University, Poznan, Poland, Biology,
1987 Ph.D., Adam Mickiewicz University, Poznan, Poland, Biology,
1992 Previous Positions Teaching Assistant, Biology Department,
Adam Mickiewicz University, Poland, 1987-92 Postdoctoral Fellow,
Department of Medical Genetics, McGill University, Canada,
1993-94 Scientific Data Analyst, National Center for Biotechnology
Information, NIH, Bethesda, 1995-97 Research Associate, National
Human Genome Research Institute, NIH, Bethesda, 1997-99 Staff
Scientist, National Human genome Research Institute, NIH,
Bethesda, 2000-2001 Professional activities Co-editor of WebAltert
section of Current Opinions in Genetics and Development, 1997-present
Ad hoc reviewer for Computer and Chemistry, Gene, and Bioinformatics
Guest Researcher, National Human Genome Research Institiute,
NIH, 2001-present Visiting Scientist, Department of Cytology
and Genetics, Charkov University, Ukraine, 1989 and 1990 Research
Interest Bioinformatics. Developing software for sequence
analysis, data storing and organization. Automation of sequence
analysis process and construction of modular systems for biological
data processing. Sequence analysis and gene identification
for positional cloning. Comparative genomics. Organization
of genes in different genomes with special focus on overlapping
genes in vertebrates and their evolution.
Recent Publications
1. Makalowska I., Ryan J., and Baxevanis A., (2001) GeneMachine:
Gene Prediction and Sequence Annotation. Bioinformatics. In
press 2. Carpten J., Makalowska I., Robbins C., Scott N.,
Sood R., Connors T., Bonner T., Smith J., Faruque M., Stephan
D., Pinkett H., Morgenbesser S., Su K., Graham C., Klingler
K., Landers G., Gregory S., Williams H., Baxevanis A., Isaacs
W., and Trent J. (2000) A 6-Mb High-Resolution Physical and
Transcription Map Encompassing the Hereditary Prostate Cancer
1 (HPC1). Genomics, 64 (1):1-14 3. Marcelino J., Carpten J.D.,
Suwairi W.M. , Gutierrez O.M, Schwartz S., Robbins C., Sood
R., Makalowska I., Baxevanis A., Johnstone B., Laxer R., Zemel
L., Kim C., Herd J.K., Ihle J., Williams C., Johnson M., Raman
V., Bahabri S.A., Trent J.M., Warman M.L., (1999 ), CACP,
encoding a secreted proteoglycan, is mutated in camptodactyl-arthropathy-coxa
vara-pericarditis syndrome. Nature Genetics 22:319-322 4.
Ferlanti E., Ryan J., Makalowska I., snd baxevanis A.D., (1999),
WebBLAST: An Integrated Solution for Organizing and Analyzing
Sequence Data, Bioinformatics: 422-423 5. Makalowska I., Ferlanti
E., Baxevanis A.D., and Landsman D., (1999) Histone sequence
database: sequences, structures, post-translational modifications
and gentic loci, Nucleic Acid Res. 27(1): 323-324
Advisory
Board member since 2001.
Financial
Donald
M. Whistler
Former VP and Senior Trust Officer for Personal Trust
Administration
in the south central Pennsylvania region with Allfirst
Trust Company, N.A. Mr. Whistler conducted the administration
of estates, trusts under will, trusts under agreement, agency
accounts, guardianships and IRA accounts assigned to his staff.
He has been active in the York community, having served on
the boards of the Rotary Club of York, the YMCA and the York
Symphony Orchestra Association. Currently he is also serving
as Chairman of the Board of the Margaret E. Moul Foundation
which oversees the management of the investment funds of the
Margaret E. Moul Home which provides facilities for disabled
individuals. Mr. Whistler is also active in numerous Masonic
organizations.
Advisory
Board member since 2001.
Joseph
P. Hackett
Comprehensive
Wealth Management with Fulton Financial Advisors
a firm managing $3.4 Billion in assets. Joe is responsible
for Investment Management, International - Foreign Currency,
Wire Transfers, Foreign Drafts, Estate Planning, Succession
Planning and Implementation, Cash Management, and Customized
Credit options. Credit options incorporate the full spectrum
of personal and commercial needs. He has been active in these
areas of financial services for almost two decades. In addition,
Mr. Hackett is active with the YMCA, The York County Chamber
of Commerce, The York Foundation, the Strand Capital, The
Cultural Alliance, Big Brothers Big Sisters, and his church.
He previously served as VP of Sales and Marketing for a regional
specialty plastics company.
Advisory
Board member since 2001.
Human
Resources & Sales
John
E. Williams,
Vice President of the Southeast for Information Technology
Resources, a unit of TMP Worldwide eResourcing. Mr.
Williams is responsible for day-to-day operations, business
development, and service delivery for the southeast region.
Mr. Williams has 10 years experience in the human capital
management industry highlighted with building effective sales
and recruitment teams that provide customized solutions for
clients' IT and Life Sciences hiring initiatives. He has a
proven track record of conceiving and executing successful
staffing strategies across the Healthcare, Life Sciences,
and Technology sectors. Most recently, he was responsible
for developing the business plan for a dedicated Life Sciences
Recruiting Practice that focused on providing the Biotech
community with top talent in early drug discovery professions.
Mr. Williams has provided enterprise solutions to the Healthcare
sector that addressed the industries' human capital management
concerns, and continues to provide workforce solutions for
the Information Technology field.
Advisory
Board member since 2002.
Technical
Forough
Ghahramani,
Founder and Principal of Life
Sciences Computing
Forough
Ghahramani is Founder and Principal of Life Sciences Computing
(www.lifesciencescomputing.com), a Princeton, New Jersey-based
consulting company that assists organizations in utilizing
high performance computing to accelerate research in the Life
Sciences. Forough Ghahramani is Dean of Business and Technology
Management at DeVry University New Jersey. Prior to her current
position, she was Chair of Biomedical Informatics and Computer
Information Systems at DeVry University Pennsylvania. Forough
has more than twenty five years diversified experience in
higher education, technology, and management. Her industry
career experience includes management consulting, technical
sales, engineering management, technical marketing management,
and systems architecture consulting. Forough's education includes
a Master of Business Administration from DePaul University,
Master of Computer Science from Villanova University, and
Bachelor of Science in Mathematics with a minor in Biology
from Pennsylvania State University. Forough's technical achievements
have been recognized with a number of awards including the
Digital Equipment Corporation Excellence Award, and the DeVry
University PRIDE award. Forough's research interests include
bioinformatics, the challenges associated with the convergence
of biotechnology and information technology. Forough is a
recognized leader in developing programs to attract, retain,
and mentor women in science, engineering, and technology fields.
Forough is a recipient of the Euro-American Women's Council's
(EAWC) Artemis award in Athens, Greece, and was inducted into
the EAWC Women's Hall of Fame on the sacred island of Delos,
birthplace of the mythical goddess Artemis, at the EAWC 10th
Annual Global Forum for her contributions and advocacy for
the future generation of women leaders in science, engineering,
and technology. Forough is a member of the New Jersey Council
on Gender Parity in Labor and Education's Committee on Science
and Technology Workforce. Forough is Director of Women's Initiative
at DeVry University Pennsylvania. She is a board member of
the Society of Women Engineers Public Policy committee, Executive
Advisory Board member of the Euro-American Women's Council,
Executive Advisory Board member and National Founding Partner
of Women Impacting Public Policy, Co-Chair of Strategic Alliances
for WIPP, and Member of the WIPP Diversity committee. Forough
is an Advisory Board member of the Eastern Technology Council's
Women's Leadership Network Group. She served as the Executive
Director of PrincetonWIT (Princeton Women, Insights, Technology)
through 2006, and past Director of Alliances for WorldWIT
(World Women, Insights, and Technology). Forough is founder
and organizer of Business Women Impacting Science and Engineering
(BWISE). Forough is also a member of BIO, the International
Biotechnology Organization, and AWIS (Association of Women
in Science). In 2008, Forough was elected to the Board of
Directors for Pennsylvania State University's Eberly College
of Science Alumni Society. She also serves on the boards of
companies and non-profit organizations. She has been featured
in Philadelphia Inquirer, Technology Times and Princeton Packet
Business Journal. She has published articles in technical
journals and presented in local, national, and international
conferences, and has served on the State of Pennsylvania Biotechnology
Education Committee. She has been an invited speaker at National
and International conferences. Forough has been instrumental
in developing programs to encourage women to pursue non-traditional
technical fields in science and engineering. Forough is a
respected leader in recruitment and retention of women in
the science, engineering, and technology and is consulted
on the local, state, and national levels with regard to workforce
development strategies.
Advisory Board member since 2001.
Life
Sciences & Bioengineering
Dr.
Ameya S. Kantak,
Technical/Biological Advisor,
Dr. Kantak joined Zerosum, Inc. in 2003 as Life Science Advisor/Bioengineer.
Since then, he has made substantial engineering contributions
to the development of Zerosum's proprietary genomic analysis
and biosensing microtechnology platforms. He has six years
of experience and expertise in BioMEMS/MEMS device fabrication
and technology, Microfluidics, Separation and sample preparation
and detection technologies. He earned his PhD in Mechanical
engineering from the University of Utah in 2005. Dr. Kantak
also holds prior degrees in Biomedical (MS, 2002) and Chemical
engineering (BS, 1998); and has authored numerous peer reviewed
international journal and conference papers, and is the co-applicant
on two related patents.
Advisory
Board member since 2003.
Dr.
Richard N. Bamford
Scientist molecular
biology
Product Development Science Advisor
Richard N. Bamford, Founder/President Transponics Dr. Bamford
earned a B.S. Degree in Biology, University of Maryland,
College Park, MD and his Ph.D. Degree, Molecular Biology,
George Washington University, Washington, DC. He recently
founded Transponics, Jacobus, PA USA, a company that offers
molecular biology and consulting services. HIs work experience
includes the Metabolism Branch, NCI, NIH, the Maryland Department
of Agriculture, a tumor biologist, Hazleton Labs Inc., Rockville,
MD, and a Staff Fellow, Medical Genetics Branch, National
Human Genome Research Institute, NIH, Bethesda, MD. Dr.
Bamford has received many honors in his career including
the 1994 CIS Science Recognition Award for New Investigators
from the Clinical Immunology Society, 1995 Outstanding Scholar
Award from the International Cytokine Society in Recognition
of Meritorious Scientific Achievement in the Field of Cytokine
Biology, 1995 American Federation for Clinical Research,
Eastern Section, Best Abstract by a Trainee, 1996 NIH Director's
Award, 1998 Inducted into the Sigma Xi Scientific Research
Society, 1999 Outstanding Merit Award for a Poster Presentation,
National Human Genome, Research Institute Retreat 2000 Abstract
Selected for Presentation at the Plenary Session of the
American Society of Human Genetics He is co-applicant in
the U.S. Patent Application: Substantially pure non-IL-2
T-cell growth factors. NIH Reference: E-131-94/0.
Publications 1. Waldmann TA, Goldman CK,
Bamford R, Burton J, Junghans RP. IL-2 receptor-directed
therapy: a model for immune intervention. In: Proceedings
of the 7th International Congress of Immunology. Berlin:
Springer-Verlag, 1989;1201-12. 2. Chan WC, Link S, Srinivasan
A, Bamford R, Waldmann TA. A T-cell line with an unusual
phenotype. Cancer 1989;64:1859-66. 3. Debatin K-M, Goldman
CK, Bamford R, Waldmann TA, Kramer PH. Monoclonal antibody
mediated apoptosis in adult T cell leukemia. Lancet 1990;335:497-500.
4. Waldmann TA, Grant A, Tendler C, Greenberg S, Goldman
C, Bamford R, Junghans RP, Nelson D. Lymphokine receptor-directed
therapy: a model of immune intervention. J Clin Immunol
1990;10:19S-29S. 5. Waldmann TA, Goldman C, Top L, Grant
A, Burton J, Bamford R, Roessler E, Horak I, Zaknoen S,
C, White J, Nelson D. The interleukin-2 receptor: a target
for immunotherapy. In: Gupta S, Waldmann TA, eds. Mechanisms
of lymphocyte activation and immune regulation IV: cellular
communications. Proceedings of the Fourth International
Conference on Lymphocyte Activation and Immune Regulation.
New York: Plenum 1992;323:57-66. 6. Waldmann TA, Goldman
C, Top L, Grant A, Burton J, Bamford R, Roessler E, Horak
I, Zaknoen S, Kasten-Sportès C, White J,England R, Horak
E, Martinucci J, Tinubu SA, Mishra B, Junghans R, Dipre
M, Carrasquillo J, Reynolds J, Gansow O, Nelson D. The interleukin-2
receptor: a target for immunotherapy. Ann N Y Acad Sci:
Immunomodulating drugs 1993;685:603-10. 7. Waldmann TA,
White J, Gansow O, Kasten-Sportès C, Roessler E, Zaknoen
S, Horak K, Carrasquillo JA, Reynolds JC, Junghans R, England
R, Goldman CK, Bamford R, Horak E, Tinubu SA, Top L, Dipre
M, Mishra B, Grant A, Nelson D. Treatment of malignant skin
diseases with genetically engineered molecules armed with
radionuclides. In: Burgdorf WHC, Katz SI, eds. Proceedings
of the 18th World Congress of Dermatology. Park Ridge, NJ:
Parthenon 1993;61-63. 8. Waldmann TA, White J, Goldman CK,
Top L, Grant A, Bamford R, Roessler E, Horak I, Zaknoen
S, Kasten-Sportès C, England R, Horak E, Mishra B, Hale
P, Fleisher TA, Junghans RP, Jaffe ES, Nelson DL. The interleukin-2
receptor: a target for anti-Tac monoclonal antibody therapy
of human T-cell lymphotropic virus I-induced adult T-cell
leukemia. Blood 1993;82:1701-12. 9. Burton JD, Bamford RN,
Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler
E, Waldmann TA. A lymphokine, provisionally designated interleukin-T,
produced by a human adult T-cell leukemia line stimulates
T-cell proliferation and the induction of lymphokine-activated
killer cells. Proc Natl Acad Sci USA 1994;91:4935-39. 10.
Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman
CK, Brennan J, Roessler E, Waldmann TA. The interleukin-2
receptor ß chain is shared by interleukin-2 and a cytokine,
provisionally designated interleukin-T, that stimulates
T-cell proliferation and the induction of lymphokine-activated
killer cells. Proc Natl Acad Sci USA 1994;91:4940-44. 11.
Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik
CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman
CK, Top LE, Bamford R, Zaknoen S, Roessler E, Kasten-Sportès
C, England R, Litou H, Johnson JA, Jackson-White T, Manns
A, Hanchard B, Junghans RP, Nelson DL. Radioimmunotherapy
of IL-2Ra-expressing adult T-cell leukemia with yttrium-90
labeled anti-Tac. Blood 1995;86:4063-75. 12. Bamford RN,
Battiata AP, Burton JD, Sharma H, Waldmann TA. Interleukin
(IL) 15/IL-T production by the adult T-cell leukemia cell
line HuT-102 is associated with a human T-cell lymphotrophic
virus type I R region/IL-15 fusion message that lacks many
upstream AUGs that normally attenuate IL-15 mRNA translation.
Proc Natl Acad Sci USA 1996;93:2897-2902. 13. Bamford RN,
Battiata AP, Waldmann TA. IL-15: the role of translational
regulation in its expression. J Leukocyte Biol 1996;59:476-80.
14. Tagaya Y, Bamford R, DeFilippis A, Waldmann TA. IL-15:
a pleiotropic cytokine with diverse receptor/signaling pathways
whose expression is controlled at multiple levels. Immunity
1996;4:329-36. 15. Waldmann TA, Bamford RN. The promiscuous
IL-2/IL-15 receptor: a target for immunotherapy. Cancer
Res 1996;37:647. 16. Bamford RN, Tagaya Y, Waldmann TA.
Interleukin-15 - what it does and how it is controlled.
The Immunologist 1997;5/2:52-56. 17. Tagaya Y, Kurys GK,
Thies TA, Losi JM, Azimi N, Hanover JA, Bamford RN, Waldmann
TA. Generation of secretable and nonsecretable interleukin
15 isoforms through alternate usage of signal peptides.
Proc Natl Acad Sci USA 1997;94:14444-49. 18. Waldmann TA,
Tagaya Y, Bamford R. Interleukin-2, Interleukin-15, and
their receptors. Intern Rev Immunol 1998:16;205-26. 19.
Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann
TA. Human T cell leukemia virus type I Tax protein trans-activates
interleukin 15 gene transcription through an NF-.B site.
Proc Natl Acad Sci USA 1998;95:2452-57. 20. Bamford RN,
DeFilippis AP, Azimi N, Kurys G, Waldmann TA. The 5' untranslated
region, signal peptide, and the coding sequence of the carboxyl
terminus IL-15 participate in its multifaceted translational
control. J Immunol 1998;160:4418-26. 21. Lehky TJ, Levin
MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS, Leist
TP, Xavier A, White JD, Brown M, Fleisher TA, Top LE, Light
S, McFarland HF, Waldmann TA, Jacobson S. Reduction in HTLV-I
proviral load and spontaneous lymphoproliferation in HTLV-I-associated
myelopathy/tropical spastic paraparesis patients treated
with humanized anti-Tac. Ann Neurol 1998;942-47. 22. Waldmann
TA, Bamford RN, Tagaya Y. The cytokine receptor family:
a target for immunotherapy. In: Kurth R, ed. Proceedings
of the 100th anniversary celebration of the Paul Ehrlich
Institute. 1999. 23. Bamford RN, Roessler E, Burdine RD,
Saplakogla U, dela Cruz J, Splitt M, Goodhip JA, Towbin
J, Bowers P, Ferrero GB, Marino B, Schier AF, Shen MM, Muenke
M, Casey B. Loss-of function mutations in the EGF-CFC gene
CFC1 are associated with human left- right laterality defects.
Nat Genet 2000;26:365-9. 24. Kurys G, Tagaya Y, Bamford
R, Hanover JA, Waldmann TA. The long signal peptide isoform
and its alternative processing direct the intracellular
trafficking of interleukin-15. J Biol Chem 2000; 275:30653-9.
25. Goldmuntz E, Bamford R, Karkera JD, dela Cruz J, Roessler
E. Muenke M. CFC1 mutations in patients with transposition
of the great arteries and double-outlet right ventricle.
Am J Hum Genet 2002;70:776-80. 26. dela Cruz JM, Bamford
RN, Burdine RD, Roessler E, Barkovich AJ, Donnai D, Schier
AF, Muenke M. A loss-of-function mutation in the CFC domain
of TDGF1 is associated with human forebrain defects. Hum
Genet 2002;110:422-8.
Advisory
Board member since 2006
.
Dr. Stanton S. Lebouitz
Bio to soon follow.
Advisory
Board member since 2007.
Point-of-care
Applications & Development
Gerald
Soucy,
Technical/Biological Advisor,
Gerald E. Soucy,
RN,
BSN, CSS Jerry earned a bachelors degree in nursing at UMass/Boston
and a graduate certificate of special studies from Harvard
University, with a concentration in health care information
technology. He has over 25 years of experience in clinical
practice and health care information technology with several
health care provider organizations as well as Fortune 100,
mid-sized, and start-up companies. Jerry gained substantial
information system sales and implementation experience by
leading and participating in system acquisition and implementation
projects with the U.S. Department of Defense/Health Affairs,
Blue Cross of California, The Cleveland Clinic Foundation,
Massachusetts General Hospital, University of Tennessee
Medical Center, Lahey Clinic, and over 35 other provider
organizations throughout the country. Jerry was a founder
and incorporator of TouchPoint Software Corporation. TouchPoint
successfully developed, sold, and installed an interactive
data acquisition and decision support tool for health care
providers - 'InfoPoint/InfoCentral.' TouchPoint was acquired
in April, 2001 by Medical Manager Corporation, a division
of WebMD (NASDAQ:HLTH). Jerry currently advises small businesses
and community organizations on ways to use information technology
through his consulting practice, e-mktg assocs. His clinical
practice focuses on patients with end-stage renal disease
(ESRD) requiring hemodialysis, where he manages a freestanding
outpatient dialysis center as well as a hospital-based acute
treatment program.
Advisory
Board member since 2003.
Dr. Thomas P. Sherwood II,
Technical/Biological learning processes applications
Advisor,
Bio
to soon follow.
Advisory Board member since 2007.
Far
East Business Planning & Development
Dr. Kalyana
Sundaram
Founder of ISeafoodXchange (S) Pte Ltd
Kalyana
is a founder of ISX and is responsible for all product development
activities and global Web operations. Kalyana holds a PhD
in Statistics and he is also involved in developing a Bio-database
and software at Nanyang Technological University, Singapore,
towards Gene discovery which comprises of the identification
of genes that are prevalently found to be expressed in a
reasonable number of patient's population. He is also in
charge of corporate strategy as well as negotiating and
forming strategic relationships and alliances in Japan,
China, Australia and Newzealand. Before forming ISX, Kalyana
worked as a consultant in Singapore for 5 years specializing
in application design, development
and implementation web based applications.
Advisory
Board member since 2002.
|
| |
|
 |
 |
 |
|
| |
© 2000-2009, Zerosum™, Inc. All Rights
Reserved
|
|
| |
|